A型肉毒毒素（BTX-A）在癌症治疗后疼痛患者治疗中的应用及疗效：系统评价和荟萃分析。
The application and therapeutic effect of botulinum toxin type a (BTX-A) in the treatment of patients with pain after cancer treatment: a systematic review and meta-analysis.
机构信息
Department of Anesthesiology, The First People's Hospital of Chenzhou, The Chenzhou Affiliated Hospital.
Department of Oncology, Graduate Collaborative Training Base of The First People's Hospital of Xiangtan City, Hengyang Medical School, University of South China, Hengyang.
出版信息
Int J Surg. 2024 Feb 1;110(2):1215-1223. doi: 10.1097/JS9.0000000000000916.
BACKGROUND
Botulinum toxin type A (BTX-A) is a potential treatment for cancer pain. This study aimed to analyze the effectiveness and safety of BTX-A in the treatment of pain after cancer treatment.
PATIENTS AND METHODS
Systematic searches of PubMed, Cochrane Library, and Embase databases were conducted. Randomized controlled trials evaluating the efficacy and safety of BTX-A compared with either placebo or active treatment in patients with pain after cancer treatment were included. The outcomes included pain intensity, quality of life, and adverse events.
RESULTS
This systematic review included four studies of which two were included in the meta-analysis. Compared with a placebo, BTX-A injection in patients with pain after cancer treatment had a clinically meaningful reduction in self-reported pain post-treatment [mean difference=-1.79 (95% CI: -2.14--1.43), P <0.00001, I ²=0%].
CONCLUSION
This systematic review and meta-analysis demonstrated that BTX-A is safe and effective for pain relief in patients with pain after cancer treatment.
背景
肉毒杆菌毒素 A（BTX-A）是治疗癌症疼痛的一种潜在方法。本研究旨在分析 BTX-A 在治疗癌症治疗后疼痛方面的疗效和安全性。
患者与方法
对 PubMed、Cochrane 图书馆和 Embase 数据库进行了系统检索。纳入了评估 BTX-A 与安慰剂或活性治疗相比在癌症治疗后疼痛患者中的疗效和安全性的随机对照试验。结果包括疼痛强度、生活质量和不良事件。
结果
本系统评价纳入了四项研究，其中两项研究纳入了荟萃分析。与安慰剂相比，BTX-A 注射治疗癌症治疗后疼痛的患者在治疗后自我报告的疼痛有明显减轻[平均差值=-1.79（95%置信区间：-2.14--1.43），P<0.00001，I²=0%]。
结论
本系统评价和荟萃分析表明，BTX-A 对癌症治疗后疼痛患者的疼痛缓解是安全有效的。
Zotero 插件